Peptide News Digest

#Q2-2026-Aftermath

2 stories

Industry · View digest

Ascendis Pharma (NASDAQ: ASND) Shares Fell Approximately 2.4% Premarket Friday August 14 to $249.28 (Compared to Thursday Close of $255.46) Despite Reporting Q2 2026 EPS of $2.83 (Beating the $1.51 Analyst Consensus by 87%) on Revenue of $339.3 Million (Beating the $326.5 Million Consensus) With Product Revenue of €315 Million (+105% Year-Over-Year) Led by YORVIPATH at €252 Million; The Market Response Reflects Investors Balancing the Substantive Beat Against the Ongoing International Trade Commission (ITC) Patent-Infringement Case Brought by BioMarin Pharmaceutical (NASDAQ: BMRN) Over the YUVIWEL (TransCon CNP for Achondroplasia) Launch That Directly Competes With BioMarin's Voxzogo (Vosoritide); BioMarin Owns U.S. Patent No. RE48,267 Covering the Peptide Analog Variants, and a First ITC Opinion Is Expected in August 2026 Following the March 26, 2026 Federal Circuit Ruling Against Ascendis on the Mandatory-Stay Question in Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc.

Ascendis Pharma (NASDAQ: ASND) shares fell approximately 2.4% premarket Friday August 14, 2026 to $249.28 (compared to Thursday close of $255.46) despite reporting Q2 2026 EPS of $2.83 (beating the $1.51 analyst consensus by 87%) on revenue of $339.3 million (beating the $326.5 million consensus). Q2 2026 product revenue reached €315 million (+105% year-over-year) led by YORVIPATH (palopegteriparatide) at €252 million, SKYTROFA (lonapegsomatropin) at €55 million, and YUVIWEL (TransCon CNP for achondroplasia) at €8 million in its first US quarter with 220+ patient enrollments through July 31. The company ended Q2 2026 with €812 million in cash, no bank or convertible debt, and expects to generate more than €500 million in operating cash flow this year. The market response reflects investors balancing the substantive beat against the ongoing International Trade Commission (ITC) patent-infringement case brought by BioMarin Pharmaceutical (NASDAQ: BMRN) over the YUVIWEL launch. BioMarin owns U.S. Patent No. RE48,267 covering peptide analog variants including its FDA-approved Voxzogo (vosoritide). A first ITC opinion is expected in August 2026 following the March 26, 2026 Federal Circuit ruling in Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc. that a party cannot use voluntary dismissal to restart a statutory deadline it already missed. The case represents the first substantive peptide-vs-peptide patent battle in the achondroplasia commercial category.

Industry · View digest

Hims & Hers Health (NYSE: HIMS) Shares Fell Approximately 6% After Hours Monday and Extended the Decline Into Tuesday August 11 Trading Despite Q2 2026 Revenue of $753.2 Million (+38% YoY, Beating $698.9M Consensus) and Q3 Guidance of $890 Million (+12.4% Above Consensus); GAAP Loss of $0.37 per Share Was Well Below Analyst Estimates, and Gross Margin Compression to 64% (From 76% Year-Ago) Hit Its Fourth Consecutive Quarter of Decline as the Compounded-to-Branded GLP-1 Pivot Continued to Drag Unit Economics; Q2 Net Loss of $86.3 Million Versus $42.5 Million Net Income in Q2 2025

Hims & Hers Health (NYSE: HIMS) shares fell approximately 6% after hours Monday and extended the decline into Tuesday August 11, 2026 trading despite Q2 2026 revenue of $753.2 million (+38% year-over-year, beating $698.9 million consensus) and Q3 guidance of $890 million at the midpoint (+12.4% above analyst expectations). The GAAP loss of $0.37 per share ran well below analyst estimates, and gross margin compression to 64% (from 76% year-ago) hit its fourth consecutive quarter of decline. Q2 net loss reached $86.3 million versus $42.5 million net income in Q2 2025. The compounded-to-branded GLP-1 pivot through the Novo Nordisk (Wegovy, Ozempic) and Eli Lilly (Zepbound, Mounjaro) commercial partnerships since Q1 2026 continues to drag unit economics. Full-year 2026 guidance was raised to $3.1-3.3 billion revenue and $275-325 million Adjusted EBITDA. The market appears to be pricing the compounded-to-branded pivot as a durable margin drag rather than a transitory transition; the July 29 FTC lawsuit alleging consumer health data sharing with Meta and Snap plus unauthorized billing charges remains a substantive overhang. Chief Medical Officer Dr. Anant Vinjamoori's July 23 PCAC harm-reduction testimony framing continues to shape the peptide-strategy narrative for the stock.